MIRABEGRON (MYRBETRIQ®) FOR OVERACTIVE BLADDER

BACKGROUND: Overactive bladder is a condition where the bladder muscle contracts involuntarily. Overactive bladder can lead to urine leakage, urgency to urinate, and frequent urination. Overactive bladder is typically treated with a class of drugs called anticholinergics. Examples include Detrol®, Ditropan®, Vesicare®, and Enablex®. Mirabegron is a new drug approved for overactive bladder that has a different mechanism of action than the anticholinergics.

MECHANISM: Mirabegron (Myrbetriq®) stimulates Beta-3 adrenergic receptors. Stimulation of Beta-3 adrenergic receptors in the bladder muscle causes it to relax.

DOSAGE: Mirabegron (Myrbetriq®) is available as a 25 and 50 mg extended-release tablet.

STUDIES: The Drug's package insert cites three 12-week studies.

SIDE EFFECTS:

CONTRAINDICATIONS / PRECAUTIONS:

DRUG INTERACTIONS:

StraightHealthcare analysis: Mirabegron has a unique mechanism that differs from the widely used anticholinergic drugs. Based on the studies presented in the package insert, its effects appear to be modest. Increases in blood pressure is a worrisome side effect. Mirabegron is a newer drug, and it will be much more expensive than the anticholinergic agents that have generics (e.g. Ditropan®, Detrol®).